Minnetronix’s Neuro division said today it completed the first trial of its Neurapheresis Therapy system exploring its use in treating patients suffering from aneurysmal subarachnoid hemorrhage.
The company’s Neurapheresis Therapy system is a minimally invasive platform, and includes a dual lumen catheter designed to be placed in the lumbar spine to filter contaminated cerebral spinal fluid to remove blood and blood breakdown byproducts, the St. Paul, Minn.-based company said. The system then returns clean cerebral spinal fluid to the patient.
In the trial, dubbed the Pillar study, investigators explored the safety, tolerability and feasibility of the system for treating patients with aneurysmal subarachnoid hemorrhage.
“There is a significant unmet need for effective treatment options for subarachnoid hemorrhage patients and I am really encouraged by the therapy’s potential to improve patient outcomes,” principal investigator Dr. Christa Swisher of Duke Health said in a prepared release.
In July, Minnetronix said it completed a 22,000-square-foot expansion of its home facilities in St. Paul, Minn.